DYMISTA 50 MCG
FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG · DIN 02432889 · BGP PHARMA ULC
Health Canada status: MARKETED
What is DYMISTA?
DYMISTA 50 MCG contains FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG. It is listed in the Health Canada Drug Product Database under DIN 02432889, held by BGP PHARMA ULC, supplied as SPRAY, METERED DOSE for NASAL administration. Health Canada currently lists it as marketed, status dated 31-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DYMISTA used for?
Symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02432889 |
|---|---|
| Brand name | DYMISTA |
| Generic / active ingredient | FLUTICASONE PROPIONATE : 50 MCG AZELASTINE HYDROCHLORIDE : 137 MCG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 50 MCG |
| Dosage form | SPRAY, METERED DOSE |
| Route of administration | NASAL |
| Schedule | Prescription |
| ATC code | R01AD58 FLUTICASONE, COMBINATIONS |
| AHFS class | 04:08.00 ; 52:02.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Jul-2018 |
| Original market date | 2015-03-31 00:00:00 |
How is it administered?
Adults and children (6+): One actuation in each nostril twice daily (morning and evening). Shake gently before use. Prime before first use (6 sprays).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refer to full monograph), though stability and disposal section is listed in TOC.
How is it supplied?
Amber glass bottles: 25 mL (at least 120 actuations) and 10 mL (at least 28 actuations). Fitted with spray pump, applicator, and dust cap.
Contraindications
Hypersensitivity to any ingredient; untreated fungal, bacterial, or tuberculosis infections of the respiratory tract.
Warnings and precautions
Risk of systemic corticosteroid effects (Cushing’s, adrenal suppression), somnolence (caution driving), local nasal effects (epistaxis, ulceration), and visual disturbances (glaucoma, cataracts).
What can be used instead?
Other Canadian products sharing ATC code R01AD58 FLUTICASONE, COMBINATIONS. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-AZELASTINE/FLUTICASONE | 137 MCG | SPRAY, METERED DOSE | APOTEX INC | MARKETED | DIN 02540886 |
| MYLAN-AZELASTINE/FLUTICASONE | 137 MCG | SPRAY, METERED DOSE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02530341 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.